Pair of deals moves Peninsula biotech closer to drug starting line

Relypsa Inc. inked a key drug-selling deal as it moved closer to regulatory approval of a new drug aimed at helping chronic kidney disease patients clear potentially fatal levels of potassium. The fast-growing Redwood City company (NASDAQ: RLYP) said Monday that it would pay Sanofi up to $10 million a year during the launch patiromer in the United States, if the Food and Drug Administration approves the drug in October. The company also said it signed a deal with Vifor Fresenius Medical Care Renal…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Source Type: news